Illumina

Illumina Earnings miss, Revenue beats In Q4

The firm reported earnings per share of $1.32 on revenue of $867M. Analysts polled by Investing.com anticipated EPS of $1.36 on revenue of $862.29M. That compared to EPS of $1.44 on revenue of $714.0M in the same period a year earlier. The company had reported EPS of $1.52 on revenue of $853M in the previous quarter.

Illumina shares lost 0.93% to trade at $282.60 in after-hours trade following the report.

...

https://finance.yahoo.com/news/illumina-...03919.html

Why Illumina Stock Is Tanking Today

What happened
Shares of Illumina (NASDAQ: ILMN) were tanking today, down 16% as of 10:27 a.m. EDT, after the genomic sequencing leader announced preliminary results for its second quarter on Thursday evening. Illumina said that it expects to report Q2 revenue of $835 million -- $50 million lower than what Wall Street analysts anticipated.

The company also updated its full-year 2019 guidance. Illumina now projects revenue growth of around 6%, less than half its previous forecast of full-year revenue growth between 13% and 14%.


...

https://finance.yahoo.com/news/why-illum...50465.html

Illumina (ILMN) Beats Q3 Earnings Estimates, Raises View

Illumina, Inc.’s ILMN third-quarter 2019 adjusted earnings per share (EPS) of $1.93 surpassed the Zacks Consensus Estimate by 37.9%. Moreover, the bottom line improved 26.9% from the year-ago quarter’s figure.

Including one-time items, the company reported EPS of $1.58, up 18.8% year over year.

Revenues

In the quarter under review, Illumina’s revenues rose 6.3% year over year to $907 million. The top line also surpassed the Zacks Consensus Estimate by 4%. The year-over-year growth can be attributed to the company’s collaborations to develop distributable clinical IVDs for Illumina sequencers.


...

https://finance.yahoo.com/news/illumina-...01269.html

Illumina (ILMN) Q4 Earnings and Revenues Top Estimates

Illumina (ILMN) came out with quarterly earnings of $1.70 per share, beating the Zacks Consensus Estimate of $1.59 per share. This compares to earnings of $1.32 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 6.92%. A quarter ago, it was expected that this genetic testing tools company would post earnings of $1.40 per share when it actually produced earnings of $1.93, delivering a surprise of 37.86%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

Illumina, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $953 million for the quarter ended December 2019, surpassing the Zacks Consensus Estimate by 0.63%. This compares to year-ago revenues of $867 million.


...

https://finance.yahoo.com/news/illumina-...10863.html

       

https://www.insidermonkey.com/blog/river...ad-971077/